Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
Abstract Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in...
Main Authors: | Jackelyn Murray, Robert J. Hogan, David E. Martin, Kathy Blahunka, Fred D. Sancilio, Rajiv Balyan, Mark Lovern, Richard Still, Ralph A. Tripp |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-09-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-97658-w |
Similar Items
-
Losartan Inhibits SARS-CoV-2 Replication in Vitro
by: Reza Nejat, et al.
Published: (2021-07-01) -
Probenecid
by: Evan C. Klein, MD, et al.
Published: (2019-08-01) -
Aprotinin Inhibits SARS-CoV-2 Replication
by: Denisa Bojkova, et al.
Published: (2020-10-01) -
Recrystallization of Probenecid Using Sonocrystallization Process
by: Chun-Hao Chang, et al.
Published: (2015) -
Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
by: Koen G. A. M. Hussaarts, et al.
Published: (2020-08-01)